Publication sur NCX-6560 (no-atorvastatine)

Scientists at University of Perugia release new data on atorvastatin

2007 DEC 17 -- According to a study from Perugia, Italy, "We compared the lipid-lowering, vasodilating, anti-thrombotic and anti-inflammatory properties of NCX 6560, a novel NO-releasing derivative of atorvastatin, with those of atorvastatin. NCX 6560 and atorvastatin induced similar inhibition of cholesterol biosynthesis in rat smooth muscle cells (IC50 = 1.9 +/- 0.4 and 3.9 +/- 1.0 mc M, respectively)."

"However, in hyperlipidemic mice, a 5-week oral treatment with NCX 6560 (46.8 mg/kg/day, p.o.) was more effective than equivalent atorvastatin (40 mg/kg/day, p.o.) at lowering serum cholesterol (NCX 6560: -21% vs controls, P< 0.05; atorvastatin: -14% vs...

Vous pourrez retrouver l'intégralité de l'article payant (3$) sur le site Newsrx.

Aucun commentaire: